Results 131 to 140 of about 8,209 (210)

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Research & Therapy
Background The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study ...
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar   +11 more
doaj   +1 more source

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study

International Journal of Dermatology, Volume 65, Issue 2, Page 299-306, February 2026.
ABSTRACT Background Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real‐world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.
Luca Potestio, Cataldo Patruno, Marika Del Gaudio, Michela Ortoncelli, Simone Ribero, Francesca Barei, Silvia Mariel Ferrucci, Laura Bonzano, Ilaria Trave, Mario Bruno Guanti, Carlotta Gurioli, Bianca Maria Piraccini, Niccolò Gori, Elena Ippoliti, Ketty Peris, Laura Grigolato, Mariateresa Rossi, Caterina Foti, Paolo Romita, Benedetta Tirone, Eustachio Nettis, Maria Esposito, Maria Concetta Fargnoli, Lina Maria Magnanimi, Elena Pezzolo, Katharina Hansel, Luca Stingeni, Rosanna Satta, Maria Mariano, Flavia Pigliacelli, Flavia Manzo Margiotta, Marco Romanelli, Ruggero Cascio Ingurgio, Antonio Costanzo, Alessandra Narcisi, Monica Corazza, Emiliano Antiga, Pietro Morrone, Pietro Rubegni, Laura Calabrese, Laura Lazzeri, Giovanni Rubegni, Fabrizio Guarneri, Nicola Zerbinati, Andrea Carugno, Rosa Valentina Puca, Oriele Sarno, Claudio Marasca, Emanuela Martina, Francesca di Vico, Maddalena Napolitano   +50 more
wiley   +1 more source

Vaccination Recommendations in Patients With Atopic Dermatitis Treated With JAK Inhibitors

International Journal of Dermatology, Volume 65, Issue 2, Page 230-237, February 2026.
Inmunization and Screening Protocol for the Safe Initiation of JAK Inhibitors. ABSTRACT Atopic dermatitis therapy has undergone a revolutionary change with the introduction of Janus kinase (JAK) inhibitors. Despite their general safety profile, these immunomodulatory drugs require special precautions with respect to infection risk and vaccine ...
Mariano Ara‐Martín, Carolina Moreno, Ricardo Ruiz‐Villaverde, Esther Serra‐Baldrich, Irene Hernández‐Martín, Maria del Pilar Fortes   +5 more
wiley   +1 more source

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review [PDF]

Atopic dermatitis (AD) is a chronic, recurrent dermatosis that affects an increasing percentage of the population. It usually affects children and resolves spontaneously, however, symptoms can persist into adulthood and even appear de novo later in life.
Frańczuk, Agata, Grzelka, Michalina, Głoskowska, Julia, Głuszczyk, Agnieszka, Karkos, Patrycja, Kopczyńska, Ewelina, Kuleta, Katarzyna, Makłowicz, Aleksandra, Plizga, Jakub, Szpulak, Angelika   +9 more
core   +1 more source

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis

Dermatology and Therapy
Introduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients’ quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment versus placebo or
Andrew Blauvelt, Kilian Eyerich, Alan D. Irvine, Marjolein de Bruin-Weller, Shawn G. Kwatra, Melinda Gooderham, Brian Kim, Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, Andrew M. Platt, Jonathan I. Silverberg   +13 more
doaj   +1 more source

Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study

Dermatology and Therapy
Introduction Phase 3 clinical trials have demonstrated robust efficacy and favorable safety of upadacitinib for the treatment of atopic dermatitis (AD). However, real-world data are still sparse.
Stephan Weidinger, Tobias Schadeck, Felix Jacobs, Ansgar Weyergraf, Dariusch Mortazawi, Tobias Hagemann, Fatima Abousamra, Thomas Mosch, Bjoern Fritz, Felix Lauffer   +9 more
doaj   +1 more source

A Joint Endeavor: Methotrexate vs. JAK Inhibitors for Joint Inflammation Reduction in Rheumatoid Arthritis [PDF]

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that causes joint inflammation and damage. This paper investigates the comparative efficacy of Janus kinase (JAK) inhibitors versus methotrexate (MTX) in reducing joint inflammation in adult ...
Kennedy, Madeleine
core   +1 more source

Long‐Term Use of Tralokinumab in Patients With Atopic Dermatitis: A Real‐World Multicentric Case Series

International Journal of Dermatology, Volume 65, Issue 2, Page 347-349, February 2026.
Christine Bangert, Barbara Ebner, Barbara Gruber, Damian Meyersburg, Judith Traxler   +4 more
wiley   +1 more source

Access Deferred Is Access Denied: Small Molecule Drug Pricing and the Future of Dermatology

International Journal of Dermatology, Volume 65, Issue 2, Page 225-226, February 2026.
Nikhita J. Perry, John S. Barbieri, Lee A. Fleisher   +2 more
wiley   +1 more source

A 17-Year-Old Male Adolescent With Refractory Crohn's Disease Managed With Upadacitinib and Risankizumab Combination Therapy: A Case Report and Review of Current Evidence. [PDF]

Am J Case Rep
Alhashemi M, Shehab M.
europepmc   +1 more source